已收盘 12-19 16:00:00 美东时间
+0.090
+2.45%
indie (Nasdaq: INDI), an automotive solutions innovator, today announced that Naixi Wu has been promoted to Chief Financial Officer, effective immediately, responsible for leading accounting and finance operations,
11-07 05:46
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! (来源:科技行者) 在全球化快速发展的今天,人工智能正在成为连接不同语言...
10-21 22:29
(来源:动脉新医药) 10月8日,诺诚健华和Zenas联合宣布,双方达成重磅授权许可协议,Zenas将获得奥布替尼在多发性硬化领域的全球开发和商业化权益,以及奥...
10-09 13:09
(来源:诺诚健华) -奥布替尼(Orelabrutinib)是一款中枢神经系统强渗透性以及高选择性的口服小分子布鲁顿酪氨酸激酶(BTK)抑制剂,有望成为Be...
10-08 17:03
金吾财讯 | 和铂医药(02142)尾盘走强,截至发稿,涨7.46%,报4.18港元,成交额2356万港元。 消息面上,和铂医药公布,集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件,以开展治疗慢性阻塞性肺病(COPD)的临床试验。 HBM9378/SKB378(现亦称WIN378)乃公司与科伦博泰开展的共同开发项目,二者共同享有大中华地区及多个东南亚及西亚国家的权利。HBM9378/SKB378是一款由两条重链及两条轻链(H2L2)平台产生的全人源单克...
02-05 16:05
金吾财讯 | 和铂医药(02142)公布,集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件,以开展治疗慢性阻塞性肺病(COPD)的临床试验。 HBM9378/SKB378(现亦称WIN378)乃公司与科伦博泰开展的共同开发项目,二者共同享有大中华地区及多个东南亚及西亚国家的权利。HBM9378/SKB378是一款由两条重链及两条轻链(H2L2)平台产生的全人源单克隆抗体。该抗体针对胸腺基质淋巴细胞生成素(TSLP),通过阻断该因子和受体的相互作用来抑制T...
02-05 13:26
The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared t o a stock’s price action,...
2024-08-29 19:31
Enables the Qi2 Magnetic Power Profile capability for convenient in-cabin wireless charging Compliant with the latest Qi standards, and qualified to automotive AEC-Q100 Grade 2 Delivers significant bill of materials savings, simplifying implementation complexity and costs indie Semiconductor (NASDAQ...
2024-08-20 21:15